help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Published ahead of print on November 9, 2006, doi:10.1164/rccm.200608-1199OC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
200608-1199OCv1
175/3/277    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Teppema, L. J.
Right arrow Articles by Poulin, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Teppema, L. J.
Right arrow Articles by Poulin, M. J.
American Journal of Respiratory and Critical Care Medicine Vol 175. pp. 277-281, (2007)
© 2007 American Thoracic Society
doi: 10.1164/rccm.200608-1199OC


Original Article

Effects of Acetazolamide on Ventilatory, Cerebrovascular, and Pulmonary Vascular Responses to Hypoxia

Luc J. Teppema*, George M. Balanos*, Craig D. Steinback, Allison D. Brown, Glen E. Foster, Henry J. Duff, Richard Leigh and Marc J. Poulin

Department of Anesthesiology, Leiden University Medical Center, Leiden, The Netherlands; School of Sport and Exercise Sciences, University of Birmingham, Birmingham, United Kingdom; and Departments of Physiology and Biophysics, Medicine, and Clinical Neurosciences, Faculty of Medicine, and Faculty of Kinesiology, University of Calgary, Calgary, Alberta, Canada

Correspondence and requests for reprints should be addressed to Marc J. Poulin, Ph.D., D.Phil., Departments of Physiology and Biophysics, and Clinical Neurosciences, Faculty of Medicine and Faculty of Kinesiology, University of Calgary, Calgary, AB, T2N 4N1 Canada. E-mail: poulin{at}ucalgary.ca

Rationale: Acute mountain sickness (AMS) may affect individuals who (rapidly) ascend to altitudes higher than 2,000–3,000 m. A more serious consequence of rapid ascent may be high-altitude pulmonary edema, a hydrostatic edema associated with increased pulmonary capillary pressures. Acetazolamide is effective against AMS, possibly by increasing ventilation and cerebral blood flow (CBF). In animals, it inhibits hypoxic pulmonary vasoconstriction.

Objectives: We examined the influence of acetazolamide on the response to hypoxia of ventilation, CBF, and pulmonary vascular resistance (PVR).

Methods: In this double-blind, placebo-controlled, randomized study, nine subjects ingested 250 mg acetazolamide every 8 h for 3 d. On the fourth test day, we measured the responses of ventilation, PVR, and CBF to acute isocapnic hypoxia (20 min) and sustained poikilocapnic hypoxia (4 h). Ventilation was measured with pneumotachography. Hypoxia was achieved with dynamic end-tidal forcing. The maximum pressure difference across the tricuspid valve ({Delta}Pmax, a good index of PVR) was measured with Doppler echocardiography. CBF was measured by transcranial Doppler ultrasound.

Results: In normoxia, acetazolamide increased ventilation and reduced {Delta}Pmax, but did not influence CBF. The ventilatory and CBF responses to acute isocapnic hypoxia were unaltered, but the rise in {Delta}Pmax was reduced by 57%. The increase in {Delta}Pmax by sustained poikilocapnic hypoxia observed after placebo was reduced by 34% after acetazolamide, the ventilatory response was increased, but the CBF response remained unaltered.

Conclusions: Acetazolamide has complex effects on ventilation, PVR, and CBF that converge to optimize brain oxygenation and may be a valuable means to prevent/treat high-altitude pulmonary edema.

Key Words: pulmonary resistance • cerebral blood flow • altitude sickness • hypoxic responses • mountaineering


AT A GLANCE COMMENTARY

Scientific Knowledge on the Subject
Acetazolamide is effective against acute mountain sickness, but the mechanisms for this effect are not completely characterized.

What This Study Adds to the Field
Acetazolamide has benefit in alleviating acute and subacute hypoxia-induced pulmonary vasoconstriction and increased pulmonary artery pressures.

 



This article has been cited by other articles:


Home page
Am. J. Respir. Crit. Care Med.Home page
J.-P. Richalet, M. Rivera-Ch, M. Maignan, C. Privat, I. Pham, J.-L. Macarlupu, O. Petitjean, and F. Leon-Velarde
Acetazolamide for Monge's Disease: Efficiency and Tolerance of 6-Month Treatment
Am. J. Respir. Crit. Care Med., June 15, 2008; 177(12): 1370 - 1376.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
R. L. Horner and T. D. Bradley
Update in Sleep and Control of Ventilation 2007
Am. J. Respir. Crit. Care Med., May 1, 2008; 177(9): 947 - 951.
[Full Text] [PDF]


Home page
ChestHome page
A. M. Luks and E. R. Swenson
Medication and Dosage Considerations in the Prophylaxis and Treatment of High-Altitude Illness
Chest, March 1, 2008; 133(3): 744 - 755.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
V. Faoro, S. Huez, S. Giltaire, A. Pavelescu, A. van Osta, J.-J. Moraine, H. Guenard, J.-B. Martinot, and R. Naeije
Effects of acetazolamide on aerobic exercise capacity and pulmonary hemodynamics at high altitudes
J Appl Physiol, October 1, 2007; 103(4): 1161 - 1165.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
E. R. Swenson and L. J. Teppema
Prevention of acute mountain sickness by acetazolamide: as yet an unfinished story
J Appl Physiol, April 1, 2007; 102(4): 1305 - 1307.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2007 American Thoracic Society
  ATS State of the Art 2009